Johnson & Johnson (NYSE:JNJ) is Woodstock Corp’s 7th Largest Position

Woodstock Corp increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,201 shares of the company’s stock after acquiring an additional 375 shares during the period. Johnson & Johnson makes up approximately 2.2% of Woodstock Corp’s portfolio, making the stock its 7th biggest holding. Woodstock Corp’s holdings in Johnson & Johnson were worth $16,287,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P grew its holdings in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. grew its holdings in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its holdings in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $152.38 on Friday. Johnson & Johnson has a twelve month low of $150.71 and a twelve month high of $186.69. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $396.84 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The business has a 50 day simple moving average of $161.97 and a 200-day simple moving average of $167.88.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Citigroup increased their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Atlantic Securities increased their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Guggenheim assumed coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $174.73.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.